Article info
PDFCase report
Bullous fixed drug eruption following administration of the recombinant adjuvant Shingrix vaccine
- Correspondence to Hallie Thompson; hallie.b.anderson{at}und.edu
Citation
Bullous fixed drug eruption following administration of the recombinant adjuvant Shingrix vaccine
Publication history
- Accepted July 31, 2021
- First published August 19, 2021.
Online issue publication
August 19, 2021
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© BMJ Publishing Group Limited 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.